Biomea Fusion (BMEA) Stock Price, News & Analysis

Company Overview

Biomea Fusion, Inc. (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction. BMF-219 is currently undergoing early-phase clinical evaluation in patients with MLL-rearranged leukemias and other malignancies driven by dysregulated menin activity. In parallel, Biomea Fusion is advancing a pipeline of preclinical programs targeting additional epigenetic and chromatin-associated proteins, all developed using its integrated discovery platform.

Founded in 2018, Biomea Fusion has assembled a multidisciplinary team of drug discovery scientists, clinical development experts and regulatory specialists. The company conducts its research and early clinical operations in the United States and is actively exploring collaborations to support later‐stage development and global commercialization. With its focus on epigenetic modulation in oncology, Biomea Fusion seeks to deliver novel treatment options for patients facing unmet medical needs.

Key Stats

• Today's Range: $1.84 to $1.98
• 50-Day Range: $1.17 to $1.94
• 52-Week Range: $0.87 to $2.99
• Volume: 1.76 million shs
• Average Volume: 1.70 million shs
• Market Capitalization: $138.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Moderate Buy

Biomea Fusion Stock Analysis - MarketRank™

Biomea Fusion scored higher than 42% of companies evaluated by MarketBeat, and ranked 622nd out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Biomea Fusion has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Biomea Fusion has a consensus price target of $9.00, representing about 371.2% upside from its current price of $1.91.

Amount of Analyst Coverage

Biomea Fusion has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Biomea Fusion are expected to decrease in the coming year, from ($0.73) to ($1.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biomea Fusion is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biomea Fusion is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biomea Fusion has a P/B Ratio of 11.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.16% of the float of Biomea Fusion has been sold short.

Short Interest Ratio / Days to Cover

Biomea Fusion has a short interest ratio ("days to cover") of 20.88, which indicates bearish sentiment.

Change versus previous month

Short interest in Biomea Fusion has recently decreased by 1.96%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biomea Fusion does not currently pay a dividend.

Dividend Growth

Biomea Fusion does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.39

News Sentiment

Biomea Fusion has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Biomea Fusion this week, compared to 3 articles on an average week.

Search Interest

7 people have searched for BMEA on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

7 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biomea Fusion insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.60% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/03/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BMEA
• CIK: 1840439
• Web: www.biomeafusion.com
• Phone: 650-980-9099
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Biomea Fusion: $9.00
• High Price Target: $12.00
• Low Price Target: $7.00
• Potential Upside/Downside: +371.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.80 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -253.73%
• Return on Assets: -97.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.47
• Quick Ratio: 3.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.17 per share
• Price / Book: 11.24

Miscellaneous

• Outstanding Shares: 72,480,000
• Free Float: 64,801,000
• Market Cap: $138.44 million
• Optionable: Optionable
• Beta: -0.23